Around one-third of the sequenced HR+/HER2− cancers harbored a PIK3CA hotspot mutation which is in line with previously reported results (The Cancer Genome Atlas Network 2012; Moynahan et al. 2017; Di Leo et al. 2018; Hortobagyi et al. 2018; André et al. 2019). Here, PIK3CA is linked to cancer.